{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:33:05Z","timestamp":1776803585467,"version":"3.51.2"},"reference-count":36,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,7,30]]},"DOI":"10.1536\/ihj.18-631","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T22:03:14Z","timestamp":1560463394000},"page":"862-869","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Characteristics and Long-Term Outcomes of Patients with Acute Decompensated Heart Failure with Mid-Range Ejection Fraction"],"prefix":"10.1536","volume":"60","author":[{"given":"Miyuki","family":"Ito","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sakakura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Ibe","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ugata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84.","DOI":"10.1016\/j.jacc.2005.09.022"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, <i>et al<\/i>. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kajimoto K, Sato N, Takano T, investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Relation of left ventricular ejection fraction and clinical features or comorbidities to outcomes among patients hospitalized for acute heart failure syndromes. Am J Cardiol 2015; 115: 334-40.","DOI":"10.1016\/j.amjcard.2014.11.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fonarow GC, Stough WG, Abraham WT, <i>et al<\/i>. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-77.","DOI":"10.1016\/j.jacc.2007.04.064"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Pitt B, Zannad F, Remme WJ, <i>et al<\/i>. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.","DOI":"10.1056\/NEJM199909023411001"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Pitt B, Segal R, Martinez FA, <i>et al<\/i>. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study, Elite). Lancet 1997; 349: 747-52.","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. K\u00f8ber L, Torp-Pedersen C, Carlsen JE, <i>et al<\/i>. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.","DOI":"10.1056\/NEJM199512213332503"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Yusuf S, Pfeffer MA, Swedberg K, <i>et al<\/i>. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the Charm-Preserved Trial. Lancet 2003; 362: 777-81.","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pitt B, Pfeffer MA, Assmann SF, <i>et al<\/i>. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-92.","DOI":"10.1056\/NEJMoa1313731"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nagai T, Yoshikawa T, Saito Y, <i>et al<\/i>. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction- A report from the Japanese heart failure syndrome with preserved ejection fraction (jasper) registry. Circ J 2018; 82: 1534-45.","DOI":"10.1253\/circj.CJ-18-0073"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cleland JG, Tendera M, Adamus J, <i>et al<\/i>. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45.","DOI":"10.1093\/eurheartj\/ehl250"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Carson P, Massie BM, McKelvie R, <i>et al<\/i>. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576-85.","DOI":"10.1016\/j.cardfail.2005.06.432"},{"key":"13","unstructured":"13. Yancy CW, Jessup M, Bozkurt B, <i>et al<\/i>. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ponikowski P, Voors AA, Anker SD, <i>et al<\/i>. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.","DOI":"10.1002\/ejhf.592"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Rickenbacher P, Kaufmann BA, Maeder MT, <i>et al<\/i>. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with congestive heart failure (Time-CHF). Eur J Heart Fail 2017; 19: 1586-96.","DOI":"10.1002\/ejhf.798"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tsuji K, Sakata Y, Nochioka K, <i>et al<\/i>. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19: 1258-69.","DOI":"10.1002\/ejhf.807"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Solomon SD, Claggett B, Lewis EF, <i>et al<\/i>. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455-62.","DOI":"10.1093\/eurheartj\/ehv464"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lund LH, Claggett B, Liu J, <i>et al<\/i>. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20: 1230-9.","DOI":"10.1002\/ejhf.1149"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.","DOI":"10.1056\/NEJM197112232852601"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J 2013; 77: 2157-201.","DOI":"10.1253\/circj.CJ-66-0068"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lang RM, Badano LP, Mor-Avi V, <i>et al<\/i>. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233-70.","DOI":"10.1093\/ehjci\/jev014"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kapoor JR, Kapoor R, Ju C, <i>et al<\/i>. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 2016; 4: 464-72.","DOI":"10.1016\/j.jchf.2016.02.017"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cheng RK, Cox M, Neely ML, <i>et al<\/i>. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168: 721-30.","DOI":"10.1016\/j.ahj.2014.07.008"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chioncel O, Lainscak M, Seferovic PM, <i>et al<\/i>. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-85.","DOI":"10.1002\/ejhf.813"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. G\u00f3mez-Otero I, Ferrero-Gregori A, Varela Rom\u00e1n A, <i>et al<\/i>. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol Engl Ed 2017; 70: 338-46.","DOI":"10.1016\/j.recesp.2016.08.019"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, <i>et al<\/i>. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol 2017; 240: 265-70.","DOI":"10.1016\/j.ijcard.2017.03.032"},{"key":"27","doi-asserted-by":"crossref","first-page":"e018719","DOI":"10.1136\/bmjopen-2017-018719","volume":"7","year":"2017","unstructured":"27. Farr\u00e9 N, Lupon J, Roig E, <i>et al<\/i>. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ Open 2017; 7: e018719.","journal-title":"BMJ Open","ISSN":"https:\/\/id.crossref.org\/issn\/2044-6055","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas \u00d3, <i>et al<\/i>. Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: findings from the RICA Registry. Int J Cardiol 2018; 255: 124-8.","DOI":"10.1016\/j.ijcard.2017.07.101"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Verma A, Meris A, Skali H, <i>et al<\/i>. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (valsartan in acute myocardial infarction) Echocardiographic Study. JACC Cardiovasc Imaging 2008; 1: 582-91.","DOI":"10.1016\/j.jcmg.2008.05.012"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yokota T, Fukushima A, Kinugawa S, Okumura T, Murohara T, Tsutsui H. Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF). Int Heart J 2018; 59: 976-82.","DOI":"10.1536\/ihj.17-560"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kinugawa K, Sato N, Inomata T. Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 2018; 59: 1368-77.","DOI":"10.1536\/ihj.18-119"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shah KS, Xu H, Matsouaka RA, <i>et al<\/i>. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017; 70: 2476-86.","DOI":"10.1016\/j.jacc.2017.08.074"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, <i>et al<\/i>. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016; 1: 510-8.","DOI":"10.1001\/jamacardio.2016.1325"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lup\u00f3n J, D\u00edez-L\u00f3pez C, de Antonio M, <i>et al<\/i>. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 2017; 19: 1615-23.","DOI":"10.1002\/ejhf.824"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kotecha D, Flather MD, Altman DG, <i>et al<\/i>. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017; 69: 2885-96.","DOI":"10.1016\/j.jacc.2017.04.001"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Cleland JGF, Bunting KV, Flather MD, <i>et al<\/i>. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39: 26-35.","DOI":"10.1093\/eurheartj\/ehx564"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/4\/60_18-631\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T03:43:40Z","timestamp":1564199020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/4\/60_18-631\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-631","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]}}}